MA41949A - Procédé de production de gonadotrophine - Google Patents

Procédé de production de gonadotrophine

Info

Publication number
MA41949A
MA41949A MA41949A MA41949A MA41949A MA 41949 A MA41949 A MA 41949A MA 41949 A MA41949 A MA 41949A MA 41949 A MA41949 A MA 41949A MA 41949 A MA41949 A MA 41949A
Authority
MA
Morocco
Prior art keywords
gonadotrophine
production process
host cell
hcg
genome
Prior art date
Application number
MA41949A
Other languages
English (en)
Other versions
MA41949B1 (fr
Inventor
Ayelet Grinhut
Daniel Plaksin
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MA41949A publication Critical patent/MA41949A/fr
Publication of MA41949B1 publication Critical patent/MA41949B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99004—Beta-galactoside alpha-2,3-sialyltransferase (2.4.99.4)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Une cellule hôte caractérisée en ce qu'elle comprend, intégrée dans son génome, une séquence codant pour la chaîne de hcg, et l'utilisation de la cellule hôte pour produire une gonadotrophine chorionique humaine hcg recombinante.
MA41949A 2015-04-24 2016-04-22 Procédé de production de gonadotrophine MA41949B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15164965 2015-04-24
PCT/EP2016/059006 WO2016170113A1 (fr) 2015-04-24 2016-04-22 Procédé de production de gonadotrophine

Publications (2)

Publication Number Publication Date
MA41949A true MA41949A (fr) 2018-02-28
MA41949B1 MA41949B1 (fr) 2020-12-31

Family

ID=53002568

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41949A MA41949B1 (fr) 2015-04-24 2016-04-22 Procédé de production de gonadotrophine

Country Status (30)

Country Link
US (1) US10464984B2 (fr)
EP (1) EP3286209B1 (fr)
JP (1) JP6964519B2 (fr)
KR (1) KR102658666B1 (fr)
CN (2) CN107532172A (fr)
AU (1) AU2016251314B2 (fr)
CA (1) CA2975449A1 (fr)
CL (1) CL2017002661A1 (fr)
CO (1) CO2017011964A2 (fr)
DK (1) DK3286209T3 (fr)
EA (1) EA034022B1 (fr)
ES (1) ES2837111T3 (fr)
HR (1) HRP20201945T1 (fr)
HU (1) HUE051879T2 (fr)
IL (1) IL253694B (fr)
LT (1) LT3286209T (fr)
MA (1) MA41949B1 (fr)
MD (1) MD3286209T2 (fr)
MX (1) MX389908B (fr)
MY (1) MY185823A (fr)
PH (1) PH12017501585B1 (fr)
PT (1) PT3286209T (fr)
RS (1) RS61163B1 (fr)
SA (1) SA517390029B1 (fr)
SG (1) SG11201706832PA (fr)
SI (1) SI3286209T1 (fr)
TN (1) TN2017000328A1 (fr)
UA (1) UA124187C2 (fr)
WO (1) WO2016170113A1 (fr)
ZA (1) ZA201707136B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120617484A (zh) 2017-09-01 2025-09-12 辉凌公司 用于受控的卵巢刺激的组合物
CN108264549A (zh) * 2018-03-29 2018-07-10 北京伟杰信生物科技有限公司 重组绒促性素rhCG的制备方法及应用
US20210038694A1 (en) 2018-04-30 2021-02-11 Ferring B.V. Composition for controlled ovarian stimulation
CN110812366B (zh) * 2019-11-18 2023-11-17 珠海丽凡达生物技术有限公司 一种可用于激素补充的mRNA药物及其制备方法
CN113337562B (zh) * 2021-05-24 2022-06-03 宁波人健药业集团股份有限公司 使用CHO细胞高效发酵生产rhCG的方法
CN121197373A (zh) * 2025-10-24 2025-12-26 北京伟杰信生物科技有限公司 一种防治母猪二胎综合征的药物组合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
AU2001231531A1 (en) * 2000-02-11 2001-08-20 Maxygen Aps Follicle stimulating hormones
US20030036181A1 (en) 2000-06-30 2003-02-20 Okkels Jens Sigurd Peptide extended glycosylated polypeptides
CN1194016C (zh) * 2000-12-29 2005-03-23 申庆祥 新的人绒毛膜促性腺激素－促黄体素融合蛋白及其制法和用途
CN101250531B (zh) * 2006-11-27 2013-04-24 株式会社Lg生命科学 一核苷酸序列、包含该序列的表达载体、该载体转化的动物细胞及利用该细胞生产人fsh的方法
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
US8326547B2 (en) * 2009-10-07 2012-12-04 Nanjingjinsirui Science & Technology Biology Corp. Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm
AU2010340358B2 (en) * 2009-12-21 2014-07-24 Pharmathene, Inc. Recombinant butyrylcholinesterases and truncates thereof
WO2013151663A1 (fr) 2012-04-02 2013-10-10 modeRNA Therapeutics Polynucléotides modifiés pour la production de protéines membranaires
CN108949772A (zh) 2012-04-02 2018-12-07 现代泰克斯公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
CN103539862B (zh) * 2013-11-01 2015-04-01 广州联康生物科技有限公司 一种长效重组促卵泡激素及其应用

Also Published As

Publication number Publication date
MD3286209T2 (ro) 2021-04-30
EA034022B1 (ru) 2019-12-19
EP3286209A1 (fr) 2018-02-28
SA517390029B1 (ar) 2021-04-04
CO2017011964A2 (es) 2018-03-09
SI3286209T1 (sl) 2021-01-29
IL253694A0 (en) 2017-09-28
MA41949B1 (fr) 2020-12-31
CN114107315A (zh) 2022-03-01
SG11201706832PA (en) 2017-09-28
CA2975449A1 (fr) 2016-10-27
PH12017501585A1 (en) 2018-02-05
ZA201707136B (en) 2022-03-30
TN2017000328A1 (en) 2019-01-16
LT3286209T (lt) 2021-02-25
AU2016251314B2 (en) 2019-12-05
EP3286209B1 (fr) 2020-11-25
MX389908B (es) 2025-03-20
US20180127477A1 (en) 2018-05-10
ES2837111T3 (es) 2021-06-29
WO2016170113A1 (fr) 2016-10-27
AU2016251314A1 (en) 2017-08-17
MY185823A (en) 2021-06-11
CL2017002661A1 (es) 2018-03-23
PT3286209T (pt) 2020-12-04
UA124187C2 (uk) 2021-08-04
HUE051879T2 (hu) 2021-03-29
KR102658666B1 (ko) 2024-04-17
US10464984B2 (en) 2019-11-05
CN114107315B (zh) 2025-01-24
HK1246325A1 (en) 2018-09-07
HRP20201945T1 (hr) 2021-02-05
JP2018512885A (ja) 2018-05-24
EA201791724A1 (ru) 2018-04-30
CN107532172A (zh) 2018-01-02
PH12017501585B1 (en) 2024-02-14
IL253694B (en) 2021-09-30
KR20170138390A (ko) 2017-12-15
MX2017010884A (es) 2017-12-07
DK3286209T3 (da) 2020-12-21
JP6964519B2 (ja) 2021-11-10
RS61163B1 (sr) 2021-01-29
BR112017016895A2 (pt) 2018-03-27

Similar Documents

Publication Publication Date Title
MA41949B1 (fr) Procédé de production de gonadotrophine
EP3583217A4 (fr) Procédé et lignée cellulaire pour la production de polycétides dans une levure
MX375911B (es) Constructos de anticuerpo multiespecifico.
CL2013002044A1 (es) Anticuerpo que une il-17a humano e il-17f humano; secuencia de adn que lo codifica; vector; celula huesped; proceso de produccion; composicion farmaceutica que lo comprende; y su uso para el tratamiento profilaxis de un trastorno patologico mediado por il-17a y/o il-17f.
EA201590994A1 (ru) Способ увеличения гидродинамического объема полипептида путем присоединения карбоксиконцевого пептида гонадотропина
PE20170704A1 (es) Agente terapeutico que induce citotoxicidad
JO3792B1 (ar) تركيبات الجسم المضاد لـ flt3 و cd3
EA201792613A1 (ru) Модуляторы cot и способы их применения
MX2023002379A (es) Proteinas de fusion de union a dr5 multivalentes y multiespecificas.
BR112016002494A2 (pt) Proteí-nas construídas com um sítio de clivagem de protease, ácido nucléico, vetor, célula e processo de engenharia de uma proteína recombinante e de um grande número de variantes de ácidos nucleicos que codificam proteínas recombinantes
MX390701B (es) Manufactura de proteína.
MA42743A1 (fr) Molécules d'anticorps multispécifiques ayant une spécificité pour tnf-alpha, il-17a et il-17f
MY181068A (en) Recombinant microorganism for improved production of fine chemicals
PL3231779T3 (pl) Proces i instalacja do wytwarzania cementu w trybie tlenowo-paliwowym
EP3649144A4 (fr) Procédé de culture cellulaire pour produire une glycoprotéine
MX377149B (es) Microorganismo recombinante para la produccion mejorada de productos quimicos finos.
Mukherjee et al. The excited states of K3 cluster: The molecular symmetry adapted non-adiabatic coupling terms and diabatic Hamiltonian matrix
EA201591720A1 (ru) Белки, специфические по отношению к baff и b7rp1, и их применение
MX2019000057A (es) Acero de alto límite de elasticidad.
EP3366776A4 (fr) Micro-organisme recombiné pour la production de l-thréonine et procédé de production de l-thréonine l'utilisant
MX2015012305A (es) Proceso para formar un articulo para el cuidado personal.
UY34640A (es) Proceso para preparar cemento, morteros y composiciones, con tratamiento de ultrafinos, y composiciones, productos de cemento, y aplicaciones.
BR112015022739A2 (pt) processo de fabricação para uma forma de dosagem efervescente
MX390436B (es) Sistemas y metodos de hidratacion.
EA201791423A1 (ru) Способ получения белка